Steensma points out in this regard that “the presence of DNMT3A, NPM1, or MLL mutations influences dose response to daunorubicin, which is used to treat AML (Acute Myelogenous Leukemia)” [18]. The gene discussed is NPM1; the disease is acute myeloid leukemia.